Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 44902-02-5 | MDL No. : | MFCD08275754 |
Formula : | C7H15NO2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | N/A |
M.W : | 145.20 g/mol | Pubchem ID : | 5312965 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.86 |
Num. rotatable bonds : | 5 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 40.24 |
TPSA : | 63.32 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.9 cm/s |
Log Po/w (iLOGP) : | 1.64 |
Log Po/w (XLOGP3) : | -1.0 |
Log Po/w (WLOGP) : | 0.98 |
Log Po/w (MLOGP) : | -1.47 |
Log Po/w (SILICOS-IT) : | 0.42 |
Consensus Log Po/w : | 0.11 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | 0.22 |
Solubility : | 241.0 mg/ml ; 1.66 mol/l |
Class : | Highly soluble |
Log S (Ali) : | 0.16 |
Solubility : | 208.0 mg/ml ; 1.43 mol/l |
Class : | Highly soluble |
Log S (SILICOS-IT) : | -0.93 |
Solubility : | 17.2 mg/ml ; 0.118 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.83 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
65% | With sodium carbonate; In 1,4-dioxane; water; at 20℃; | The unprotected aminoheptanoic acid derivative (100 mg, 0.689 mmol, 1.00 equiv) wasdissolved in 10% Na2CO3 solution (2.0 mL) and dioxane (1.0 mL) and Fmoc-OSu (256 mg,0.759 mmol, 1.10 equiv) was added. The mixture was allowed to warm to rt and stirredovernight. The reaction was quenched by the addition of water (30 mL). The aqueous layer waswashed with diethyl ether (1 × 50 mL). The aqueous layer was acidified with HCl to pH = 2 andextracted with dichloromethane (4 × 50 mL). The combined organic phases were dried oversodium sulfate, filtered, and concentrated in vacuo. The crude product was purified by reversedphasepreparative HPLC using linear CH3CN/H2O gradients containing 0.1% trifluoroacetic acid(TFA). Identification was carried out by ESI-ToF MS and NMR spectroscopy. The N-Fmocprotected amino acid was obtained as white solid. Yield: 165 mg (0.449 mmol, 65%).1H NMR (500 MHz, C3D6O): delta = 0.88-0.91 (m, 3 H, CH3), 1.28-1.38 (m, 4 H, (CH2)2CH3), 1.42-1.50 (m, 2 H, CH2CH2CHCO2H), 1.70-1.78 (m, 1 H, CH2CH2CHCO2H), 1.84-1.91 (m, 1 H,CH2CH2CHCO2H), 4.21-4.27 (m, 2 H, COOCH2CH), CHCO2H), 4.33 (d, J = 7.2 Hz, 2 H,COOCH2CH), 7.30-7.34 (m, 2 H, Ar), 7.39-7.42 (m, 2 H, Ar), 7.71-7.73 (m, 2 H, Ar), 7.86 (d, J =7.5 Hz, 2 H, Ar) ppm signals for NH and COOH were not found; 13C NMR (126 MHz,S18C3D6O): delta = 14.3 (CH3), 23.1 (CH2CH2CH3), 26.2 (CH2CH2CHCO2H), 32.1 (CH2CH2CH3), 32.5 (CH2CHCO2H), 48.0 (COOCH2CH), 54.7 (CHCO2H), 67.1 (COOCH2CH), 120.8 (Ar-C), 126.2 (Ar-C), 127.9 (Ar-C), 128.5 (Ar-C), 142.1 (Ar-C), 145.0 (Ar-C), 157.1 (COOCH2), 174.1 (COOH) ppm; HRMS (ESI): m/z [M + Na]+ calcd. for [C22H25NNaO4]+: 390.1676; found: 390.1684. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With hydrogenchloride; In water; at 120℃; for 3h; | General procedure: Compounds 1 and 2 (1mg each) were hydrolysed with 6MHCl (1ml) at 120 C for 3 h. The solutions were then evaporatedto dryness, and the residues were re-dissolved in 1mlof water and dried on a rotary evaporator. Next, 100 mul of 1Msodium bicarbonate was added to each residue to form solutions.Amino acid standards were also individually dissolvedin 100 mul of 1M sodium bicarbonate at concentrations of1mgml-1. The D, L-aminoheptanoic acid were purchasedfrom Aladdin Biochemical Technology and J&K Scientific.Thirty-five microlitres of Nalpha-(2,4-dinitro-5-fluorophenyl)-L-alaninamide (L-FDAA, Marfey?s Reagent, for threonine,leucine and tryptophan) [26] and 60mul Nalpha-(2,4-dinitro-5-fluorophenyl)-D/L-leucinamide (D/L-FDLA, advanced Marfey?sreagent, for alpha-aminoheptanoic acid) [27] in acetone(10mgml-1) was added to each solution. The solutions wereincubated in a water bath at 55 C for 1 h. After cooling toroom temperature, each solution was dissolved in MeCN forHPLC analysis. At 26 C, MeCN/H2O containing 0.1%HCOOH was used as mobile phase using the following gradient:0-5min, 20% MeCN; 5-35 min, 20-60% MeCN;35-40min, 60-100% MeCN and 40-50 min, 100-20%MeCN. The flow rate was 1 ml min-1 with UV detection at340 nm. The HPLC results for the amino acids were comparedto the results of the standard samples [26]. |
[ 5408-52-6 ]
(S)-2,6-Diaminohexanoic acid (S)-2-aminopentanedioic acid salt
Similarity: 1.00